Telavancin Option to Treat Bacterial Pneumonia Infections
By Louise Gagnon
TORONTO -- November 1, 2017 -- Telavancin is effective as a second-line therapy in the treatment of pneumonia, according to data from the Telavancin Observational Use Registry (TOUR) presented here at the 2017 Annual Meeting of the American College of CHEST Physicians.
The antibacterial agent telavancin, a derivative of vancomycin, is approved for use to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in the United States when alternative therapies are not suitable, explained Micah Jacobs, MD, FACP, Romano, Pontzer & Associates, Pittsburgh, Pennsylvania, on October 30.
Data from 46 sites in the United States, representing >1,000 patients, were gathered, and a subset of patients who had lower respiratory tract infections (LRTIs) was identified. Demographic information, antibiotic therapy, pathogens, dosage, duration of therapy, clinical outcome, and adverse events were analysed, with clinical outcomes evaluated through a retrospective chart review.
A total of 98 patients (median age, 59 years) had LRTIs. MRSA to be the most common pathogen in patients. An organism was identified in 91 patients, of whom 52 (53.1%) had MRSA. Thirty-three patients (33.7%) had ≥2 pathogens.
In 77 patients (78.6%), telavancin was used as a second-line agent after failure of previous therapy. A total of 15 patients (15.3%) failed ≥2 therapies. Fifty-two patients (53.1%) had a positive clinical response, defined as either a cure or improvement, to use of step-down oral therapy.
“Using it as a second-line therapy, we were seeing impressive efficacy,” said Dr. Jacobs. “When you are dealing with pneumonia and LRTIs, it is key that we have highly effective agents that are able to treat LRTIs.”
Telavancin represents another treatment choice, apart from vancomycin, said Dr. Jacobs, noting that it has advantages, such as once-daily dosing and potency.
In terms of toxicities, treatment-emergent adverse events, such as cardiac arrest, renal failure, respiratory shock, and septic shock, occurred, but only renal failure was thought to be related to treatment. Of 9 serious adverse events, 6 resulted in deaths not related to the use of telavancin, and infections resolved in the remaining 3 cases.
The study was funded by Theravance.
[Real-World Treatment of Lower Respiratory Tract Infections in the Telavancin Observational Use Registry (TOUR). Abstract]